title: Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients.
abstract: Adjuvant bisphosphonate therapy is increasingly used in postmenopausal breast cancer patients. This is based on level-one evidence that bisphosphonates, particularly zoledronic acid, can effectively prevent cancer treatment-induced bone loss in breast cancer patients receiving estradiol-lowering endocrine therapies such as aromatase inhibitors. Furthermore, emerging data from large clinical trials suggest that additional anticancer benefits can be derived due to a positive impact on the bone marrow microenvironment.
authors.affiliation: Universitátsklinikfür Chirurgie, Medizinische Universität Wien, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Gnant